Literature DB >> 11737076

Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases.

H Brühl1, K Wagner, H Kellner, M Schattenkirchner, D Schlöndorff, M Mack.   

Abstract

Chemokine receptors play a crucial role in the recruitment of leucocyte subsets into inflamed tissue. Using FACS analysis we have studied the surface expression of different CC- and CXC-chemokine receptors on synovial fluid (SF) and peripheral blood leucocytes from 20 patients with various forms of arthritis. In the SF the majority T cells stained positive for CCR5 (93%) and CCR2 (57%), compared to the peripheral blood (36% and 25%). In addition, most of the T cells expressed CXCR4 in both compartments, with a somewhat higher percentage in the SF (90%) versus peripheral blood (83%). To date little information is available on chemokine receptor expression on monocytes in arthritis. We report a marked increase of CCR5(+) monocytes in the SF (87%) compared to the peripheral blood (22%). In contrast, the frequency of CXCR1(+), CXCR2(+), CXCR4(+) and CCR1(+) monocytes was considerably lower in the SF than in the peripheral blood. Moreover, we report the expression CXCR4 on neutrophils in the SF. Approximately 60% of neutrophils stained positive for CXCR4 in the SF, while in the peripheral blood the number of CXCR4(+) neutrophils was low (24%). Surface expression of CXCR1 and CXCR2 was significantly reduced on SF neutrophils (53% and 68%) compared to the peripheral blood. Chemokine receptors are differentially expressed on leucocyte subsets in arthritis. The identification of their pattern of expression might help to identify suitable targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737076      PMCID: PMC1906244          DOI: 10.1046/j.1365-2249.2001.01679.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Chemically synthesized SDF-1alpha analogue, N33A, is a potent chemotactic agent for CXCR4/Fusin/LESTR-expressing human leukocytes.

Authors:  H Ueda; M A Siani; W Gong; D A Thompson; G G Brown; J M Wang
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

2.  The delta32 deletion of CCR5 receptor in rheumatoid arthritis.

Authors:  S P Cooke; G Forrest; P J Venables; A Hajeer
Journal:  Arthritis Rheum       Date:  1998-06

3.  Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN-gamma.

Authors:  G Penton-Rol; N Polentarutti; W Luini; A Borsatti; R Mancinelli; A Sica; S Sozzani; A Mantovani
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

4.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.

Authors:  S Qin; J B Rottman; P Myers; N Kassam; M Weinblatt; M Loetscher; A E Koch; B Moser; C R Mackay
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  Detection and delineation of CXCR-4 (fusin) as an entry and fusion cofactor for T-tropic [correction of T cell-tropic] HIV-1 by three different monoclonal antibodies.

Authors:  T Hori; H Sakaida; A Sato; T Nakajima; H Shida; O Yoshie; T Uchiyama
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

6.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.

Authors:  C C Bleul; L Wu; J A Hoxie; T A Springer; C R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

7.  HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.

Authors:  R Walli; B Reinhart; B Luckow; E Lederer; O Loch; A Malo; R Wank; D Schlöndorff; F D Goebel
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-07-01

8.  Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.

Authors:  F Sallusto; D Lenig; C R Mackay; A Lanzavecchia
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

9.  A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)

Authors:  C C Bleul; R C Fuhlbrigge; J M Casasnovas; A Aiuti; T A Springer
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

10.  Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.

Authors:  M Mack; B Luckow; P J Nelson; J Cihak; G Simmons; P R Clapham; N Signoret; M Marsh; M Stangassinger; F Borlat; T N Wells; D Schlöndorff; A E Proudfoot
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

View more
  19 in total

1.  T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.

Authors:  P Kivisäkk; C Trebst; Z Liu; B H Tucky; T L Sørensen; R A Rudick; M Mack; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

2.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

3.  Regulation of human neutrophil chemokine receptor expression and function by activation of Toll-like receptors 2 and 4.

Authors:  Ian Sabroe; Elizabeth C Jones; Moira K B Whyte; Steven K Dower
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 4.  Chemokines in homeostasis and diseases.

Authors:  Keqiang Chen; Zhiyao Bao; Peng Tang; Wanghua Gong; Teizo Yoshimura; Ji Ming Wang
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 5.  The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis.

Authors:  Marlon P Quinones; Carlos A Estrada; Yogeshwar Kalkonde; Sunil K Ahuja; William A Kuziel; Matthias Mack; Seema S Ahuja
Journal:  J Mol Med (Berl)       Date:  2005-04-13       Impact factor: 4.599

6.  Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders.

Authors:  T Ellingsen; N Hornung; B K Møller; J H Poulsen; K Stengaard-Pedersen
Journal:  Ann Rheum Dis       Date:  2006-08-11       Impact factor: 19.103

7.  In vivo imaging implicates CCR2(+) monocytes as regulators of neutrophil recruitment during arthritis.

Authors:  Baomei Wang; Bernd H Zinselmeyer; Herbert A Runnels; Timothy P LaBranche; Phillip A Morton; Daniel Kreisel; Matthias Mack; Cheryl Nickerson-Nutter; Paul M Allen; Mark J Miller
Journal:  Cell Immunol       Date:  2012-08-04       Impact factor: 4.868

8.  Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis.

Authors:  Marlon P Quinones; Sunil K Ahuja; Fabio Jimenez; Jason Schaefer; Edgar Garavito; Arun Rao; George Chenaux; Robert L Reddick; William A Kuziel; Seema S Ahuja
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

9.  Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.

Authors:  M Margarida Souto-Carneiro; Vijayabhanu Mahadevan; Kazuki Takada; Ruth Fritsch-Stork; Toshihiro Nanki; Margaret Brown; Thomas A Fleisher; Mildred Wilson; Raphaela Goldbach-Mansky; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2009-06-05       Impact factor: 5.156

10.  Glycosaminoglycan analogs as a novel anti-inflammatory strategy.

Authors:  India C Severin; Adriano Soares; Jennifer Hantson; Mauro Teixeira; Daniela Sachs; Delphine Valognes; Alexander Scheer; Matthias K Schwarz; Timothy N C Wells; Amanda E I Proudfoot; Jeffrey Shaw
Journal:  Front Immunol       Date:  2012-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.